VRDN
HEALTHCAREViridian Therapeutics Inc
$17.53-1.22 (-6.51%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VRDN Today?
No stock-specific AI insight has been generated for VRDN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.07$34.29
$17.53
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-3.35
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume7.8M
Avg Volume (10D)—
Shares Outstanding103.1M
VRDN News
22 articles- Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh FundraisingYahoo Finance·May 8, 2026
- Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their EstimatesYahoo Finance·May 7, 2026
- Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionYahoo Finance·May 7, 2026
- Viridian Therapeutics’ stock up 35% after Phase III TED data releaseClinicaltrialsarena·May 6, 2026
- Viridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TEDMarketbeat·May 6, 2026
- Viridian (VRDN) Climbs 33% on Looming Drug CommercializationYahoo Finance·May 6, 2026
- How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye DiseaseYahoo Finance·May 5, 2026
- Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred StockYahoo Finance·May 5, 2026
- PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 ResultsAdvfn·May 5, 2026
- Viridian data lift prospects for thyroid eye disease drugBiopharmadive·May 5, 2026
- Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent ProgressYahoo Finance·May 5, 2026
- Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye DiseaseYahoo Finance·May 5, 2026
- Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)Yahoo Finance·Apr 26, 2026
- Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-YearYahoo Finance·Apr 22, 2026
- Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should KnowThe Motley Fool·Apr 21, 2026
- Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20%Yahoo Finance·Apr 21, 2026
- Truist Cuts PT on Viridian Therapeutics (VRDN) to $36 From $40Yahoo Finance·Apr 20, 2026
- Evercore ISI Adjusts Viridian Therapeutics, Inc. (VRDN) Outlook in Pre-Earnings PreviewYahoo Finance·Apr 17, 2026
- Viridian Therapeutics price target lowered to $36 from $40 at TruistYahoo Finance·Apr 9, 2026
- A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi‑Month Share Price PullbackYahoo Finance·Apr 8, 2026
- J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire Inc.·Apr 1, 2026
- Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire Inc.·Mar 31, 2026
All 22 articles loaded
Price Data
Open$19.07
Previous Close$18.75
Day High$20.00
Day Low$17.42
52 Week High$34.29
52 Week Low$12.07
52-Week Range
$12.07$34.29
$17.53
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-3.35
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume7.8M
Avg Volume (10D)—
Shares Outstanding103.1M
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—